UK insurers have said that they may seek approval to use the results of genetic tests for cancer from next year. Søren Holm believes they should have to pass the results on to insurance companies, but Richard Ashcroft argues that the risks of disclosure justify privacy in most cases
No takes yet. Share an insight, caveat, or question.
Richard Ashcroft (2007) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: